Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.73 |
| ▸ | CASP6 | P55212 | 1/20 | 0.74 |
| ▸ | HTR2A | P28223 | 5/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.73 |
| ▸ | HTR2B | P41595 | 4/20 | 0.73 |
| ▸ | HTR2C | P28335 | 4/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alosetron SCHEMBL7371660 | 1.00 | CASP6 (0.74) | CASP6HTR2AKCNH2HTR2BHTR2C | |
| Alosetron SCHEMBL148316 | 0.99 | HTR2A (0.74) | CASP6HTR2AKCNH2HTR2BHTR2C | |
| Alosetron SCHEMBL2229995 | 0.92 | KCNH2 (0.65) | CASP6HTR2AKCNH2HTR2BHTR2C | |
| SCHEMBL20027463 | 0.87 | KCNH2 (0.57) | CASP6HTR2AKCNH2HTR2BHTR2C | |
| SCHEMBL20022665 | 0.86 | HTR2A (0.56) | CASP6HTR2AKCNH2HTR2BHTR2C | |
| Alosetron SCHEMBL29387635 | 0.85 | CASP6 (1.00) | CASP6HTR2AKCNH2HTR2BHTR2C | |
| Alosetron SCHEMBL806 | 0.85 | CASP6 (1.00) | CASP6HTR2AKCNH2HTR2BHTR2C | |
| Alosetron SCHEMBL631 | 0.84 | KCNH2 (1.00) | CASP6HTR2AKCNH2HTR2BHTR2C | |
| Alosetron SCHEMBL29377019 | 0.84 | KCNH2 (1.00) | CASP6HTR2AKCNH2HTR2BHTR2C | |
| SCHEMBL3321223 | 0.83 | KCNH2 (0.54) | CASP6HTR2AKCNH2HTR2BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2058 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170147-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170149-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| WO-2025075714-A1 | POINT-OF-CARE TEST DIAGNOSTIC MARKERS AND ADJUVANT TREATMENTS FOR GASTROINTESTINAL DISEASES | ROWAN UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| EP-4259153-A1 | NOVEL USE OF PYRROLOPYRIDINE DERIVATIVES FOR PREVENTING OR TREATING INFLAMMATORY DISEASES | Voronoi Inc. (KR) | 2023-10-18 | — | — | EP | claimed |
| WO-2023164386-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023163879-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| US-20060116350-A1 | Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE | 2006-06-01 | — | — | US | claimed |
| WO-2006052626-A2 | DOPAMINE 3 RECEPTOR AGONIST AND ANTAGONIST TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-05-18 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1603544-A1 | TREATMENT OF INTESTINAL CONDITIONS WITH N-2,3,3-TETRAMETHYLBICYCLO 2.2.1 HEPTAN-2-AMINE | AGI Therapeutics Ltd. (IE) | 2005-12-14 | — | — | EP | claimed |
| US-20040209961-A1 | Treatment of intestinal conditions with N-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine | AGI THERAPEUTICS LIMITED (IE) | 2004-10-21 | — | — | US | claimed |
| WO-2004080446-A1 | TREATMENT OF INTESTINAL CONDITIONS WITH N-2,3,3-TETRAMETHYLBICYCLO[2.2.1]HEPTAN-2-AMINE | AGI THERAPEUTICS LTD. (US) | 2004-09-23 | — | — | WO | claimed |
| WO-2003100091-A1 | MEANS AND METHODS FOR IMPROVED TREATMENT USING 'SETRONES' | EPIDAUROS BIOTECHNOLOGIE AG (DE) | 2003-12-04 | — | — | WO | claimed |
| CN-1281357-A | Medicaments | GLAXO GROUP LTD (GB) | 2001-01-24 | — | — | CN | claimed |